Trial of MK-1242 (vericiguat) in subjects with heart failure with reduced EF
VICTORIA: A randomized, placebo-controlled, parallel-group, multi-centered, double-blind, event driven trial of MK-1242 (vericiguat) in subjects with heart failure with reduced ejection fraction (HFrEF). The safety and efficacy of MK-1242 (vericiguat) compared to placebo, on a background of standard of care will be evaluated. Vericiguat is a novel oral soluble guanylate cyclase stimulator in development for chronic HF.
Questions: Call Mary Soltau 303-703-2191 or Rebecca Wimmer 303-715-2275